GOLDEN, CO / ACCESSWIRE / April 30, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma one of the world’s emerging biotechnology companies focused on allogeneic Mesenchymal Stem Cell (“MSC”) research and clinical products including AlloRx Stem Cells™, Brain Grow Technologies™ NutraVivo™ Stem Cell Activator, and the MSC-Gro™ Brand Stem Cell Culture Media has been awarded Certification to the International Organization for Standardization (ISO) Quality Standard 13485:2016 for medical devices.

This certification further strengthens Vitro Biopharma’s quality management system that is ISO 9001:2015 and CLIA certified. Regulatory certifications encompass our quality system, clinical diagnostics and cGMP manufacturing based on our commitment to attaining customer satisfaction and seeking continual improvement as a primary goal. We use risk assessment guidance, extensive control systems encompassing outside service providers, manufacturing, process & product validation, and new product development in the operation of our quality system. Vitro Biopharma is FDA-registered and operates within a broad regulatory umbrella and platform suitable for FDA-compliant drug/biologics and medical device manufacturing.

Vitro Biopharma is executing its business model based on supporting IRB-approved stem cell therapies in off-shore locations that are now yielding evidence of safety and efficacy. This goal requires compliance to internationally recognized standards such as ISO 9001 & ISO 13485 to gain clinical trial approvals in global medical tourism destinations. The recent IRB approval of our clinical trial entitled “Vitro Biopharma Allogeneic Mesenchymal Stem Cell
Therapy for Musculoskeletal Conditions” in the Bahamas was facilitated by our ISO certification. Through our partner, DVC Stem, in Grand Cayman Island we provide AlloRx
Stem Cells™ to support an IRB-approved trial determining the effects of MSC transplants on various inflammatory conditions. We provide our MSC-Gro™ stem cell culture medium to support clinical trials of MSC therapy for osteoarthritis (OA). These trials and several others totaling 2385 patients and pre-clinical studies in 20,000 animals provide evidence of safety and efficacy. In the US alone there are more the 30 million OA patients. The standard of care is joint replacement, but emerging evidence suggests that a single MSC injection into afflicted joints can regenerate cartilage, reduce pain, restore functionality and defer replacement at a fraction of the cost of joint replacement. We have gained preliminary evidence of safety and efficacy of AlloRx Stem Cell™ therapy of neurodegenerative diseases through clinical studies in New Zealand. Our regulatory certifications support further expansion into other medical tourism markets as well as clinical trials leading to US approvals. The FDA is in the process of adopting ISO 13485 as its quality standard for medical devices and full legal implementation is anticipated in 2020.

Dr. Jim Musick, CEO of Vitro Biopharma said, “We are extremely pleased with this milestone accomplishment as we have recently focused on achieving ISO 9001:2015, ISO 13485:2016 and CLIA certifications. This provides necessary support for our goal of suppling offshore medical tourism destinations with high quality AlloRx Stem Cells™ for various applications in regenerative medicine. AlloRx Stem Cells™ are distinctly superior to “stem cell” clinics operating in the US that are restricted to “minimally manipulated” products that contain limited stem cell content at very low purity and do not achieve international standards of stem cell definition. Adipose-derived allogeneic MSCs (Allofisel™) have been recently approved by the European Medicines Agency for treatment of a type of Crohn’s disease. These are expanded and purified stem cells that presently require pre-market FDA approval in the US as drugs. Offshore venues allow studies of expanded and purified MSCs wherein the identity, purity and potency are clearly established. Several clinical studies support the concept that adequate stem cell dosage is critical in determining therapeutic outcomes. There are variations in the known types of adult MSCs and our patent-pending AlloRx Stem Cells™ are superior to other known adult stem cells.”

About Vitro Biopharma

Vitro Biopharma, for over 10 years, has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with Mesenchymal Stem Cells, MSC-Grow™ Brand of cell culture media, various stem cell derivatives and stem cell-derived differentiated cells. We also supply primary fibroblast cells and an expanding line of cancer-associated fibroblasts (CAFs) from various tumors including lung, breast, melanoma, pancreatic and colorectal tissues. Our CAFs are purchased by major pharmaceutical and biopharmaceutical firms to advance immunotherapy of cancer.

We now support clinical studies of stem cell therapies for osteoarthritis, neurodegenerative diseases including Parkinson’s disease, Multiple Sclerosis and Alzheimer’s disease while pursuing select US markets for stem cell therapies. We support high quality offshore medical tourism with the DaVinci Wellness Centre, our clinical trial partner in the Cayman Islands www.DVCStem.com.

We provide Brain Grow Technologies™
NutraVivo™ Stem Cell Activator that has been shown to induce proliferation, migration and epigenetic modification of human adult stem cells. NutraVivo™ improves overall cellular wellness and significantly increases expression of anti-aging genes.

We private label Limitless MD™ cosmetic products for topical applications in skin beautification.

About the International Organization for Standardization (ISO)

The International Organization for Standardization (ISO) (www.iso.org) is the world’s largest developer and publisher of International Standards. It is comprised of national standards bodies from 159 countries that promote high quality standards for all company processes. To meet ISO certification requirements for Quality Management Systems, companies must establish a well-tuned system of interacting processes that ensures consistent quality of the company’s products; their capacity to optimally meet customer requirements; and their fulfillment of all applicable regulatory requirements.

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 1
E-mail: jim@vitrobiopharma.com
www.vitrobiopharma.com

SOURCE: Vitro Diagnostics, Inc.

ReleaseID: 543561

Sip on Tea, Nibble on Treats and Enjoy a Day of Pampering, While Raising Money for Kids Battling Cancer

CALGARY, AB / ACCESSWIRE / April 30, 2019 / On Sunday May 12, 2019 from 2:00 to 4:00 pm, Helping Families Handle Cancer will host their Third Annual Mother’s Day Tea, taking place at the Sundance Lake Resident Association (63 Suncrest Way SE, Calgary AB). Eighty plus Moms and their families will enjoy an Old-fashioned High Tea. Proceeds of this event benefit Helping Families Handle Cancer Care Program.

Tickets are available at www.mothersdayteayyc.com
Tickets are $10/child or $20/adult
Special VIP Tables for 8 available for $200

After being diagnosed with childhood cancer at the age 13 months old, and battling cancer until she was 6, thirty-three-year-old Carie Stock founded Helping Families Handle Cancer (HFHC). This charity helps families with the expenses that come along with having a child battling cancer at the Alberta Children’s Hospital.

“I always had a hard time deciding what to surprise my Mom with on Mother’s Day. Always looking for the perfect gift, I realized that the only thing my Mom would truly want on Mother’s Day is to spend time with our family. Rather than taking my Mom to the same boring brunch that is hard to get reservations for, I thought, what about hosting a Mother’s Day Tea?” said Carie Stock, Founder and Executive Director of Helping Families Handle Cancer. “As a little girl, we dreamed of sipping on tea and having miniature treats. What a great outing for Calgary families this Mother’s Day. While sipping on tea and eating treats, participants will be helping less fortunate families who have a child battling cancer.”

(Pictures from the Mother’s Day Tea in 2018)

TEA PARTY DETAILS

WHEN
Sunday, May 12, 2019
2:00 PM to 4:00 PM

WHERE
Sundance Lake Resident Association

63 Suncrest Way SE, Calgary

WHAT
Moms celebrate Mother’s Day by enjoying an old-fashioned tea party,while raising money for Helping Families Handle Cancer

MEDIA LIAISON

Carie Stock, Executive Director & Founder
Helping Families Handle Cancer
C 403 850 5477 carie@helpingfamilieshandlecancer.com

INTERVIEWS

Carie Stock
Founder and Executive Director
Helping Families Handle Cancer
C 403 850 5477
carie@helpingfamilieshandlecancer.com

*Cancer family who benefited from our Care Program, available upon request

ABOUT HELPING FAMILIES HANDLE CANCER

Helping Families Handle Cancer is a not-for-profit organization that strives to alleviate some of the stress of childhood cancer by providing financial support to families in need, due to the time commitment at the hospital, in caring for their child. The Helping Families Care Program purchases items such as parking passes, medical supplies, medication not covered through benefits, rent, gas, groceries and other household bills that families are struggling to pay for as they take time away from work to be with their child during this critical time. To date, Helping Families has helped over 825 families at the Alberta Children’s Hospital with over $650,000 in financial support, giving more precious time with their litter hero!

SOURCE: Helping Families Handle Cancer

ReleaseID: 543401

BOCA RATON, FL / ACCESSWIRE / April 30, 2019 / Ominto, Inc. (OTC PINK: OMNT), a growth company with global operations in the e-commerce industry, announced today that it has submitted an offer of settlement to the Securities and Exchange Commission proposing to agree to a Commission order revoking the registration of its securities pursuant to Section 12 of the Securities Exchange Act. Upon the entry of such an order, trading in the company’s securities will cease. The company is not able to predict when the order will be entered. Once entered, shares can only be sold in private transactions as there will not be any recognized trading on a public exchange marketplace.

Michael Hansen, Founder and CEO of Ominto stated, “This solution satisfies our intent and priority to become current with our audits as soon as possible. By revoking our registration with the SEC, it provides us the necessary time and resources to become current with our audits much faster and in a cost-effective manner. Once our audits are complete, we intend to apply for listing on Nasdaq.”

About Ominto, Inc.

Ominto is a growing company with global operations in e-commerce. The company owns or invests in strategic entities that provide value to its global customer base.

Ominto is a pioneer in global Cash Back and first to market in many regions of the world. At the core of Ominto’s business is Dubli.com, a global consumer Cash Back website. At Dubli.com, consumers shop at their favorite stores, save with the best coupons and deals, and earn Cash Back with each purchase. Dubli.com features thousands of brand name stores and industry-leading travel companies from around the world, providing Cash Back savings to consumers in more than 120 countries. Ominto’s BSP Rewards programs offer a co-branded version of Dubli.com to businesses and nonprofits, providing them with a professional, reliable web presence that builds brand loyalty with their members, customers or constituents while earning commissions for the organization and Cash Back for shoppers on each transaction.

For more information, please visit Ominto’s corporate website http://ominto.com.

Forward-looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These include statements about Ominto’s expectations, beliefs, intentions or strategies for the future, which are indicated by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “believe,” “projects,” “could,” “would,” and similar expressions. You can also identify them by the fact that they do not relate strictly to historical or current facts. The forward-looking statements reflect Ominto’s current view about future events and are subject to risks, uncertainties and assumptions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Ominto may not actually achieve the expectations disclosed in the forward-looking statements and you should not place undue reliance on Ominto’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results or events to differ materially from the expectations disclosed in the forward-looking statements, including, but not limited to: risks related to our ability to continue as a going concern being in doubt; Ominto’s inability to generate enough customers or enough purchasing activity for our shopping websites; Ominto’s inability to establish and maintain a large growing base of Business Associates; Ominto’s failure to adapt to technological change; increased competition; increased operating costs; changes in legislation applicable to Ominto’s business; Ominto’s failure to improve our internal controls; and Ominto’s inability to generate sufficient cash flows from operations or to secure capital to enable us to maintain our current operations or support our intended growth; along with other risks and potential factors that could affect Ominto’s business and financial results identified in Ominto’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2016.

Contact:

Michael Hansen

investorrelations@ominto.com

SOURCE: Ominto, Inc.

ReleaseID: 543526

DIDCOT, UK / ACCESSWIRE / April 30, 2019 / Altus Strategies Plc (AIM: ALS & TSX-V: ALTS), the Africa focused royalty and project generator, announces that it has published its Management Discussion & Analysis for the quarter and year ended 31 December 2018. This document has been posted on the Company’s website www.altus-strategies.com and is also available on SEDAR at www.sedar.com.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

For further information you are invited to visit the Company’s website www.altus-strategies.com or contact:

Altus Strategies Plc

Steven Poulton, Chief Executive

Tel: +44 (0) 1235 511 767

E: info@altus-strategies.com

SP Angel (Nominated Adviser)

Richard Morrison / Soltan Tagiev

Tel: +44 (0) 20 3470 0470

SP Angel (Broker)

Richard Parlons / Jonathan Williams

Tel: +44 (0) 20 3470 0471

Blytheweigh (Financial PR)

Tim Blythe / Camilla Horsfall

Tel: +44 (0) 20 7138 3204

About Altus Strategies Plc

Altus is a London (AIM: ALS) and Toronto (TSX-V: ALTS) listed royalty and project generator in the mining sector with a focus on Africa. Our team creates value by making mineral discoveries across multiple licences. We enter joint ventures with respected groups and our partners earn interest in these discoveries by advancing them toward production. Project milestone payments we receive are reinvested to extend our portfolio, accelerating our growth. The portfolio model reduces risk as our interests are diversified by commodity and by country. The royalties generated from our portfolio of projects are designed to yield sustainable long term income. We engage constructively with all our stakeholders, working diligently to minimise our environmental impact and to promote positive economic and social outcomes in the communities where we operate.

SOURCE: Altus Strategies Plc

ReleaseID: 543510